Date: 2016-11-21
Type of information: Licensing agreement
Compound: BL-1230
Company: BiolineRx (Israel) Yissum Research Development Company of the Hebrew University of Jerusalem (Israel)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing
Action mechanism: cannabinoid receptor agonist. BL-1230 is a potent and selective cannabinoid receptor type 2 (CB2R) agonist developed by Professor Raphael Mechoulam from the Department of Medicinal Chemistry and Natural Products at the Faculty of Medicine of the Hebrew University. The involvement of CB2R in immune modulation is well established, and pre-clinical studies in three ocular inflammatory models have demonstrated that BL-1230 eye drops have significant anti-inflammatory activity, which attenuates the pathology and improves histological outcomes. In addition to DES, BioLineRx intends to explore the potential use of this compound in systemic inflammatory conditions.
Disease: dry eye syndrome
Details: * On November 21, 2016, BioLineRx announced that it has signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., for the in-licensing of a novel anti-inflammatory treatment for Dry Eye Syndrome (DES). This project, to be named BL-1230, is the third project in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
Financial terms:
Latest news:
